Jinlixi (xeligekimab) / Genrix Bio - LARVOL DELTA

Can Acrodermatitis Continua of Hallopeau with Moderate-to-Severe Nail Involvement Be Effectively Controlled? A Real-World, 24-Week Study of 17 Cases Treated via Periungual Injection of the Novel IL-17A Inhibitor Xeligekimab Combined with Tofacitinib (EADV 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Dermatitis • Dermatology • Immunology • IL17A

Efficacy and safety of xeligekimab in moderate-to-severe plaque psoriasis patients with lower limbs lesions: a single-center, prospective, observational study (EADV 2026) - No abstract available

Clinical • Observational data • Dermatology • Immunology • Plaque Psoriasis • Psoriasis

A Distinct Rosacea-Mimicking Facial Inflammatory Phenotype in Psoriasis: Preliminary Evidence for Synchronous Response to IL-17A Blockade with Xeligekimab (EADV 2026) - No abstract available

Dermatology • Immunology • Psoriasis • Rosacea

Ccf-mtDNA as a potential biomarker for assessing treatment response and relapse in plaque psoriasis during Xeligekimab therapy (EADV 2026) - No abstract available

Biomarker • Dermatology • Immunology • Plaque Psoriasis • Psoriasis

Xeligekimab Achieves Sustained Joint and Skin Improvement in Psoriatic Arthritis: A Real-World Subgroup Analysis from a Prospective, Multicenter, Observational Study in China (XP-Real) (EADV 2026) - No abstract available

Clinical • Observational data • Real-world • Real-world evidence • Immunology • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Real-World Effectiveness and Patient-Reported Outcomes of Xeligekimab in Moderate-to-Severe Plaque Psoriasis With Challenging Clinical Profiles: A Prospective, Multicenter, Observational Study in China (XP-Real) (EADV 2026) - No abstract available

Clinical • Observational data • Patient reported outcomes • Real-world • Real-world effectiveness • Real-world evidence • Dermatology • Immunology • Plaque Psoriasis • Psoriasis

A Single-Arm Exploratory Study to Evaluate the Efficacy and Safety of Recombinant Fully Human Anti-IL-17A Monoclonal Antibody Injection (GR1501) in the Treatment of Refractory Gout (ChiCTR) - P=N/A | N=15 | Not yet recruiting | Sponsor: Affiliated Hospital of North Sichuan Medical College; Affiliated Hospital of North Sichuan Medical College

New trial • Gout • Inflammatory Arthritis • Rheumatology

Real-world study of treatment with Xeligekimab in patients with moderate to severe plaque psoriasis in Xinjiang region (ChiCTR) - P=N/A | N=100 | Recruiting | Sponsor: Peoples Hospital of Xinjiang Uygur Autonomous Region; Peoples Hospital of Xinjiang Uygur Autonomous Region

New trial • Real-world evidence • Dermatology • Immunology • Psoriasis

Case Report: Successful treatment of refractory generalized pustular psoriasis with xeligekimab: a report of two cases. (PubMed, Front Immunol) - "Both patients- a 25-year-old male and a 70-year-old male had long-standing GPP that was unresponsive to conventional systemic therapies including acitretin and methotrexate. Remarkably, one patient remained in remission at the 3-month follow-up after only one injection. This is the first report to suggest that xeligekimab is a potent and promising therapeutic option for inducing rapid and sustained remission in patients with GPP."

Journal • Dermatology • Immunology • Psoriasis • Pustular Psoriasis • IL17A

Case Report: Local injection of an IL-17 inhibitor successfully treats Acrodermatitis continua of Hallopeau and avoids immune shift. (PubMed, Front Immunol) - "A 13-year-old female patient with ACH showed poor responses to systemic acitretin, upadacitinib, and topical calcipotriol/betamethasone. After switching to systemic Xeligekimab, her hand and foot pustules improved rapidly, but eczematous eruptions appeared...The Palmoplantar Pustulosis Area and Severity Index (PPPASI), Dermatology Life Quality Index (DLQI), and Nail Psoriasis Severity Index (NAPSI) all decreased substantially, and no immune drift recurred. This case suggests that local injection of an IL-17 inhibitor may effectively control skin lesions while potentially avoiding systemic immune imbalance, offering a preliminary novel treatment approach for refractory ACH that requires further validation."

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Psoriasis • Pustular Psoriasis • IL17A

Efficacy of xeligekimab in patients with active radiographic axial spondyloarthritis with and without elevated C-reactive protein or erythrocyte sedimentation rate: a post-hoc analysis of a phase III randomized clinical trial (EULAR 2026) - P3 | "Conclusions Xeligekimab demonstrated robust efficacy in r-axSpA patients regardless of baseline CRP or ESR. A higher proportion of patients returned to normal CRP or ESR levels at week 16 after receiving xeligekimab."

Clinical • P3 data • Retrospective data • Ankylosing Spondylitis • Immunology • Inflammatory Arthritis • Seronegative Spondyloarthropathies • Spondylarthritis • CRP • IL17A

Xeligekimab improved enthesitis at Achilles tendon sites in patients with radiographic axial spondyloarthritis: 48-week results of a phase III randomized controlled trial (EULAR 2026) - P3 | "After data from xeligekimab-treated patients were pooled (n=189), xeligekimab-treated group demonstrated significant improvement in enthesitis at Achilles tendon sites compared to placebo at both week 16 (mean change: -0.15 [95% CI: -0.20, -0.11] vs. -0.12 [95% CI: -0.19, -0.06]; p < 0.05) and week 48 (mean change: -0.15 [95% CI: -0.20, -0.11] vs. -0.13 [95% CI: -0.20, -0.07]; p < 0.05) (Table 2). Conclusions Xeligekimab provides significant and sustained therapeutic benefit for enthesitis at Achilles tendon sites in patients with active r-axSpA throughout treatment period."

Clinical • P3 data • Ankylosing Spondylitis • Immunology • Inflammatory Arthritis • Seronegative Spondyloarthropathies • Spondylarthritis • IL17A

Periungual Injection of the Novel IL-17A Inhibitor Xeligekimab Combined with Tofacitinib for Acrodermatitis Continua of Hallopeau (ACH): A Prospective, Real-World, 12-Week Study (EADV-Sp 2026) - "(C) Comparison of Dermatology Life Quality Index(DLQI) scores between baseline and post-12-week treatment. Boxes include the median and interquartile range.**P<0.05 by Student's t-test Conclusions This preliminary study demonstrates that periungual xeligekimab combined with tofacitinib is an effective and well- tolerated therapeutic strategy for refractory ACH, offering significant improvements in both nail signs and quality of life."

Clinical • Real-world • Real-world evidence • Addiction (Opioid and Alcohol) • Dermatitis • Dermatology • Immunology • Infectious Disease • Inflammation • Psoriasis • Pustular Psoriasis • Respiratory Diseases • IL17A

Efficacy and Safety of Xeligekimab Compared to Other IL-17A Inhibitors for Chinese Patients with Moderate-to-severe Plaque Psoriasis: A Matching-adjusted Indirect Comparisons. (PubMed, Acta Derm Venereol) - "This study evaluated the comparative effectiveness of Xeligekimab vs Secukinumab and Ixekizumab through matchingadjusted indirect comparisons (MAICs). At week 60, Xeligekimab maintained significantly higher PASI 75 vs Ixekizumab (92.6% vs 76.1%, p<0.001) with lower infection rates during induction period (7.9% vs 34.7%, p<0.001) and maintenance period (22.4% vs 56.5%, p<0.001). This MAIC provides hypothesis-enerating evidence that Xeligekimab may offer advantages in specific long-term efficacy endpoints and safety outcomes, requiring confirmation in direct randomized controlled trials."

Clinical • Journal • Dermatology • Immunology • Infectious Disease • Psoriasis • IL17A

Case Report: The First Case of Paradoxical Skin Lesions Induced by Xeligekimab in a Patient With SAPHO Syndrome. (PubMed, Int J Rheum Dis) - No abstract available

Journal

Efficacy and safety of Xeligekimab (GR1501) in the treatment of axial Spondyloarthritis: Results from a Phase II clinical trial. (PubMed, Rheumatol Immunol Res) - "No treatment-emergent anti-drug antibodies were detected. Xeligekimab at 100 mg and 200 mg achieved meaningful clinical improvement with good tolerability in patients with active axSpA, supporting further clinical evaluation of this therapy."

Clinical • Journal • P2 data • Ankylosing Spondylitis • Immunology • Inflammatory Arthritis • Seronegative Spondyloarthropathies • Spondylarthritis • IL17A

Clinical Observation of Xeligekimab in the Treatment of Moderate to Severe Palmoplantar Pustulosis (clinicaltrials.gov) - P4 | N=10 | Recruiting | Sponsor: First Hospital of China Medical University

New P4 trial • Immunology • Psoriasis

Switching within the Class of IL-17 Inhibitors for the Treatment of Plaque Psoriasis: Efficacy and Safety Results from a Single-Center Study (AAD 2026) - "The study suggest that performing an intraclass switch among IL-17 inhibitors is a generally effective and safe option. Xeligekimab has the potential to better meet the requirements of treat-to-target therapy for patients."

Clinical • Dermatology • Immunology • Plaque Psoriasis • Psoriasis • IL17A

Efficacy and safety of xeligekimab in adult patients with pityriasis rubra pilaris: A Single-Arm, Open-Label Clinical Trial (AAD 2026) - "In this single-armed trial, xeligekimab demonstrated significant efficacy and a favorable safety profile in patients with severe PRP, positioning it as a promising therapeutic option."

Clinical • IL17A

Case Report: Periungual Xeligekimab injection for refractory Acrodermatitis continua of Hallopeau. (PubMed, Front Immunol) - "Prior therapies, including topical corticosteroids, phototherapy, and systemic tofacitinib, had proven ineffective. This escalation resulted in marked clinical resolution: complete clearance of pustules and inflammation, healthy nail regrowth, and resolution of digital swelling and pain. Concurrently, the Dermatology Life Quality Index and pain scores dramatically improved, and follow-up MRI showed substantial resolution of the underlying bone marrow edema, confirming the treatment's efficacy on both cutaneous and deep osseous inflammation."

Journal • Dermatitis • Dermatology • Immunology • Inflammation • Pain • IL17A

A Comprehensive Multicenter Clinical Evaluation of Xeligekimab in the Treatment of Moderate-to-Severe Psoriasis (ChiCTR) - P=N/A | N=200 | Not yet recruiting | Sponsor: Chongqing Hospital of Traditional Chinese Medicine; Chongqing Hospital of Traditional Chinese Medicine

New trial • Dermatology • Immunology • Psoriasis • Psoriatic Arthritis

Model-Based Meta-Analysis of IL-17 A Inhibitors for Moderate-to-Severe Plaque Psoriasis: Establishing Exposure-Response Relationships to Inform Targeted Drug Development. (PubMed, Clin Rev Allergy Immunol) - "This study aimed to establish an exposure-response model for IL-17 A inhibitors to predict the clinical efficacy of novel agents based on in vitro potency and pharmacokinetic parameters, guiding the development of new IL-17 A-targeting therapies. A systematic literature search was conducted in PubMed, Cochrane Library, and Embase to identify randomized controlled trials of three FDA-approved IL-17 A inhibitors: secukinumab, ixekizumab, and bimekizumab. External validation showed high predictive accuracy for xeligekimab. A reference table was also constructed to estimate required doses based on IC50 and desired therapeutic targets, facilitating rational dose selection. Based on existing pharmacokinetic and clinical efficacy data of IL-17 A inhibitors, this study successfully developed a streamlined and accurate exposure-response model, offers a practical tool for efficacy prediction and dose optimization in the development of novel agents..."

Clinical • Journal • Retrospective data • Review • Dermatology • Immunology • Psoriasis • IL17A

Efficacy and Safety of Xeligekimab in the Treatment of Non-Radiographic Axial Spondyloarthritis (clinicaltrials.gov) - P2/3 | N=40 | Not yet recruiting | Sponsor: Lingli Dong

New P2/3 trial • Ankylosing Spondylitis • Immunology • Seronegative Spondyloarthropathies • Spondylarthritis • CRP

Xeligekimab, an Interleukin-17A Antagonist for Active Radiographic Axial Spondyloarthritis in Chinese Patients: 16- and 48-Week Results from a Phase III, Randomized, Double-Blind, Placebo-Controlled Study. (PubMed, BioDrugs) - P3 | "Xeligekimab demonstrated significant efficacy in improving the signs and symptoms of active r-axSpA in Chinese patients at week 16, with sustained effects observed through week 48 and no new safety signals identified."

Clinical • Journal • P3 data • Ankylosing Spondylitis • Dermatology • Immunology • Inflammatory Arthritis • Psoriasis • Seronegative Spondyloarthropathies • Spondylarthritis • IL17A

Efficacy and Safety of Biologics to Treat Adults With Active Radiographic Axial Spondyloarthritis: Systematic Review and Bayesian Network Meta-Analysis (ISPOR-EU 2025) - "OBJECTIVES: To compare efficacy and safety of IL-17 inhibitors in the treatment of adults with active radiographic axial spondyloarthritis (r-AxSpA) over a 16-week period using network meta-analysis (NMA). We conducted systematic literature search in PubMed and Embase in November 2024 to retrieve publications with results of randomized controlled trials (RCTs) evaluating efficacy and safety of IL-17 inhibitors (netakimab, secukinumab, ixekizumab, bimekizumab, brodalumab, xeligekimab, vunakizumab) in adults with active r-AxSpA... Netakimab showed the highest relative efficacy among available IL-17 inhibitors used to treat adults with active r-AxSpA over 16-week horizon and demonstrated a favorable safety profile."

Retrospective data • Review • Ankylosing Spondylitis • Immunology • Inflammatory Arthritis • Seronegative Spondyloarthropathies • Spondylarthritis • IL17A